Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Regulatory News | 11 August 2016 | By Zachary Brennan
The European Medicines Agency (EMA) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) on Thursday released new draft guidance and a question and answer document to help ensure that data integrity is maintained during the process of testing, manufacturing, packaging, distributing and monitoring medicines.
The 44-page PIC/S draft guidance, known as “Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments,” is focused on providing industry with “consolidated, illustrative guidance on risk-based control strategies” for data integrity and reliability as described in PIC/S Guides for GMP and GDP.
The release of the EMA and PIC/S guidance follows the US Food and Drug Administration’s (FDA) release of draft guidance on data integrity in GMP manufacturing in April.
The 13-page guidance includes 18 questions and answers on data integrity, alongside well-defined terms on data as they relate to cGMP records, as well as recommendations on when workflows on computer systems need to be validated, and how to ensure electronic master production and control records (MPCR) are monitored and can only be used by authorized personnel.
The release of the guidance follows an increase in the number of concerns over data manipulation and other data integrity questions in manufacturing facilities based in India, China and elsewhere.
The new draft guidance document from PIC/S, which will be applied on a six-month trial basis by the 49 PIC/S participating authorities, defines and deals with:
“Management should aim to create a work environment (ie. quality culture) that is transparent and open, one in which personnel are encouraged to freely communicate failures and mistakes, including potential data reliability issues, so that corrective and preventative actions can be taken,” the draft reads.
The draft also details the various deficiencies linked to data integrity failures that may have varying impacts on product quality:
Impact to product with risk to patient health:
Impact to product with no risk to patient health:
No impact to product; evidence of widespread failure:
No impact to product; limited evidence of failure:
In addition to the draft guidance, EMA released 23 questions and answers on data integrity, which were developed by EMA’s GMP / Good Distribution Practice (GDP) Inspectors Working Group.
The stakeholder advice includes measures that ensure data integrity and minimize risks at all stages of the data lifecycle in pharmaceutical quality systems. The advice applies to both paper-based and electronic systems and specifically addresses:
EMA notes that the Q&A document should be read in conjunction with national guidance, medicines legislation and the GMP standards published in Eudralex volume 4.
Tags: PIC/S, data integrity of medicines during manufacturing, pharmaceutical manufacturing, GMP drug manufacturing